Heska Corporation HSKA
Heska is a low-growth animal-health distributor — not the innovator management claims — masquerading at a 9x-sales SaaS multiple; Spruce Point sees 50-60% downside to $90-$115.
Thesis
Spruce Point argues Heska, a $2.8bn-market-cap animal health equipment company, has quietly repackaged itself from a stagnant distributor into an 'innovator' narrative through six low-quality acquisitions and aggressive promotion. Their forensic analysis finds organic revenue actually declined at a -1.2% CAGR from 2017-2020, adjusted EBITDA margins collapsed from 20% to 8%, and CEO Kevin Wilson's growth story masks material governance red flags — egregious compensation, related-party dealings with Wilson-owned Cuattro, nepotism (brother on payroll), and $18m of insider selling. Yet the stock trades at 9x 2022E sales, in line with SaaS peers and dominant leader IDEXX, despite Heska lacking IDEXX's margins, scale, and IP. Spruce Point's sum-of-the-parts analysis pegs fair value at $90-$115, implying 50-60% downside, and flags ESG concerns including an undisclosed mercury disposal incident.
SCQA
Heska Corporation is a $2.8bn animal-health equipment company marketed to investors as a transformed innovator and market-share gainer in the booming companion-animal diagnostics space.
Forensic analysis shows organic revenue declined -1.2% CAGR 2017-2020, margins collapsed, and the 'growth' is acquisition-fueled financial engineering obscured by CEO Wilson's conflicts, insider selling, and ESG red flags.
Spruce Point urges investors to sell Heska, recognize that its 9x-sales valuation is irrational for a distributor, and re-rate the stock to reflect its true distributor-like economics.
Spruce Point's sum-of-the-parts model values Heska at $90-$115 per share, implying approximately 50-60% downside from the $228.86 price on 10/22/2021.
The three reasons
- 1
Heska's 'organic growth' is an illusion: real 2017-2020 CAGR was -1.2%, margins collapsed from 20% to 8%
- 2
Distributor priced like SaaS at 9x 2022E sales; ex-acquisitions, core Heska trades at 17.5x — in-line with vastly superior IDEXX
- 3
CEO Wilson: $18m insider selling, brother on payroll, egregious comp, Cuattro conflicts, and undisclosed mercury ESG incident
Primary demands
- Sell Heska shares (Strong Sell opinion)
- Re-rate stock to reflect distributor-like economics rather than SaaS/innovator multiple
- Revoke Piper Sandler research coverage for conflicted underwriter relationship
- Scrutinize CEO Kevin Wilson's conflicts, compensation, and related-party dealings
KPIs cited
Pattern membership
Precedents cited
- Spruce Point's July 2019 PetIQ short (animal-health track record)
- Spruce Point's September 2018 Henry Schein/Covetrus long (animal-health track record)
- MusclePharm SEC case (same auditor connection)
Composition what's on the 128 slides
Slide gallery ·
Notes
Classic long-form Spruce Point short report (128 pages). Memorable cover: white cat in blue litter box with skull-and-crossbones and fleeing rat, captioned 'Scoop This Poop From Your Portfolio'. Opens with a track-record comparison slide (PetIQ short vs. Henry Schein long) to establish credibility in animal-health sector — a signature Spruce Point framing device. Deck blends forensic accounting (organic-growth reconstruction on p.13), governance red-flag cataloging (Cuattro relationships, nepotism, auditor ties), ESG attack (mercury disposal), and peer-multiple plus sum-of-the-parts valuation. Author_name null: cover and disclaimer credit only 'Spruce Point Capital Management LLC'; founder Ben Axler is not named on cover.